NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
PR Newswire
WASHINGTON, Aug. 22, 2026
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural Freedom 250 Grand Prix of Washington, D.C., the first-ever NTT INDYCAR SERIES race on the National Mall.
The event, taking place August 22–23, 2026, celebrates America's 250th anniversary with high-speed racing on a 1.7-mile, seven-turn temporary street circuit framed by the Washington Monument, U.S. Capitol, and other iconic landmarks. Practice and qualifying occur Saturday, with the 147-lap, approximately 250-mile race scheduled for Sunday afternoon and broadcast live on FOX.
NEREUS™ (tradipitant), the first new U.S. prescription medication approved for the prevention of motion-induced vomiting in 47 years, is the primary sponsor of the No. 47 Honda. The partnership, announced by Vanda, aligns the brand's focus on performance and stability with the demands of IndyCar racing. This weekend marks a home event for the Washington-based company.
"Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda.
Fans can follow the No. 47 NEREUS™ IndyCar as Schumacher and Rahal Letterman Lanigan Racing take on this landmark street circuit in the nation's capital.
About NEREUS™ (tradipitant)
NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com and follow us on X @vandapharma.
About Rahal Letterman Lanigan Racing
Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
SOURCE Vanda Pharmaceuticals Inc.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States